27 Apr 2022 15:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx to Present at the American Society of Clinical Oncology (ASCO) Annual Meeting
Alderley Park, 27 April 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces it will present a poster on RXC004 at the forthcoming American Society of Clinical Oncology (ASCO) Annual Meeting, (3-7 June 2022, Chicago, US/virtual).
RXC004 is the Company's lead oncology asset. It is a potent, orally active porcupine inhibitor in clinical development as a targeted therapy for Wnt-ligand driven cancer. It is currently in Phase 1 clinical studies in combination with nivolumab, an anti-PD-1 antibody, and is also being evaluated as a monotherapy in Phase 2 proof-of-concept clinical studies for the treatment of genetically selected pancreatic cancer, genetically selected metastatic colorectal cancer and unselected biliary cancer
Title: | A Multi-arm, Phase 2, Open-Label Study to Assess the Efficacy of RXC004 as Monotherapy and in Combination with Nivolumab, in Patients with Ring Finger Protein 43 (RNF43) or R-Spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable Colorectal Cancer, following standard treatment
|
Abstract: | TPS3637 |
Day/Date: |
Saturday 4 June 2022, 08:00 AM - 11:00 AM CDT
|
Session name and category: | Poster Session/Gastrointestinal Cancer - Colorectal and Anal |
The abstract will be available from 26 May via the ASCO Annual Meeting website at: http://ASCO.org/abstracts
The poster will also be available on the Company's website at: https://www.redxpharma.com/scientific-publications/
For further information, please contact: |
|
|
|
Redx Pharma Plc Caitlin Pearson, Head of Communications ir@redxpharma.com
UK Headquarters Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 |
US Office Peter Collum, Chief Financial Officer |
|
|
|
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
Matt Davis/ Adam Dawes |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 |
Claes Spång/ Satheesh Nadarajah/ David Wilson |
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 |
Rupert Dearden/ Freddy Crossley/ Emma Earl |
|
|
|
FTI Consulting | T: +44 (0)203 727 1000 |
Simon Conway/ Ciara Martin |
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Encouraging safety and pharmacokinetic data has been reported, and a Phase 2 clinical program is confirmed to start in 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/